#1 Clinical Trials Search in Europe

Neflamapimod

Neflamapimod is an investigational drug being studied in clinical trials for its potential benefits in treating various neurodegenerative disorders, including dementia with Lewy bodies (DLB), Huntington’s disease, and Alzheimer’s disease. This article summarizes key information from several clinical trials examining the effects of neflamapimod on cognitive function, motor symptoms, and disease biomarkers in patients with these conditions.

Table of Contents

What is Neflamapimod?

Neflamapimod, also known by its alternative name VX-745, is an experimental drug that is being studied for its potential to treat various neurodegenerative diseases[2][3][4]. It is a highly specific inhibitor of an enzyme called p38 alpha kinase, which is involved in inflammation and cellular stress responses[2]. This drug is currently in clinical trials and is not yet approved for general use.

Conditions Treated by Neflamapimod

Neflamapimod is being investigated for its potential to treat several neurodegenerative conditions, including:

  • Dementia with Lewy Bodies (DLB): A type of dementia that affects thinking, memory, and movement[1][2]
  • Huntington’s Disease: A genetic disorder that causes progressive brain damage[3]
  • Alzheimer’s Disease: The most common form of dementia, affecting memory, thinking, and behavior[4]

How Neflamapimod Works

Neflamapimod works by targeting a specific enzyme in the body called p38 alpha kinase. This enzyme is involved in processes that can lead to inflammation and cellular stress in the brain. By inhibiting this enzyme, neflamapimod may help to reduce harmful inflammation and protect brain cells from damage[2].

In neurodegenerative diseases like Dementia with Lewy Bodies, Huntington’s Disease, and Alzheimer’s Disease, there is often increased inflammation and stress in the brain. By reducing these harmful processes, neflamapimod aims to slow down or potentially reverse some of the damage caused by these conditions[1][3][4].

Clinical Trials and Research

Neflamapimod is currently being studied in several clinical trials:

  • Dementia with Lewy Bodies (DLB) Studies: Two studies are investigating the effects of neflamapimod on cognitive function, motor symptoms, and overall disease status in patients with DLB[1][2].
  • Huntington’s Disease Study: A study is looking at whether neflamapimod can improve spatial learning and other cognitive functions in patients with early-stage Huntington’s Disease[3].
  • Alzheimer’s Disease Study: A trial is examining if neflamapimod can improve memory function and slow disease progression in patients with mild Alzheimer’s Disease[4].

Potential Benefits of Neflamapimod

Based on the ongoing clinical trials, neflamapimod may potentially offer several benefits for patients with neurodegenerative diseases:

  • Improved Cognitive Function: Studies are assessing whether the drug can enhance learning, memory, and problem-solving skills[1][2][4].
  • Enhanced Motor Function: Some trials are looking at whether neflamapimod can improve movement and reduce the risk of falls in patients with DLB[1][2].
  • Reduced Neuropsychiatric Symptoms: The drug may help alleviate symptoms like hallucinations, depression, and agitation in DLB patients[2].
  • Slowed Disease Progression: Researchers are investigating if neflamapimod can slow down the overall progression of these neurodegenerative diseases[4].

How Neflamapimod is Administered

In the clinical trials, neflamapimod is typically administered as follows:

  • It is taken orally in the form of capsules[1][2][4].
  • The dosage is usually 40 mg per capsule[1][2][4].
  • It is typically taken two or three times daily with food[1][2][4].
  • The duration of treatment in these trials ranges from 10 to 24 weeks[3][4].

Future Prospects

While neflamapimod shows promise in early clinical trials, it’s important to note that it is still an experimental drug. More research is needed to fully understand its effectiveness and safety profile. If the ongoing trials show positive results, neflamapimod could potentially become an important treatment option for patients with neurodegenerative diseases in the future[1][2][3][4].

Condition Trial Phase Key Outcomes Measured Dosing
Dementia with Lewy Bodies (DLB) Phase 2a, 2b CDR-SB, TUG test, NPI, cognitive tests, EEG 40-80 mg, 2-3 times daily
Huntington’s Disease Phase 2 Virtual Morris Water Maze Test, CANTAB 40 mg, twice daily
Alzheimer’s Disease Phase 2b HVLT-R, WMS, CDR-SB, MMSE, CSF biomarkers 40 mg, twice daily

FAQ

  • What is neflamapimod? Neflamapimod is an investigational drug that specifically inhibits an enzyme called p38 alpha kinase. It is being studied for its potential to improve cognitive function and other symptoms in neurodegenerative disorders.
  • Which conditions are being studied with neflamapimod? Clinical trials are examining neflamapimod's effects in dementia with Lewy bodies (DLB), Huntington's disease, and Alzheimer's disease.
  • How is neflamapimod administered in these trials? Neflamapimod is typically given as oral capsules, taken two or three times daily with food. The dosage varies between trials but is often 40-80 mg per dose.
  • What are the main outcomes being measured in these trials? The trials are primarily assessing changes in cognitive function, using various tests and scales. Some trials also measure motor function, neuropsychiatric symptoms, and biomarkers in cerebrospinal fluid or brain imaging.
  • Are there any known side effects of neflamapimod? While specific side effect information is not provided in the trial summaries, the studies are monitoring for adverse events and safety. More detailed safety information would be available in the full trial results.

Ongoing Clinical Trials on Neflamapimod

  • Study on Neflamapimod for Patients with Dementia with Lewy Bodies

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Neflamapimod for Treating Dementia with Lewy Bodies in Patients Aged 55 and Older

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Dementia with Lewy bodies (DLB): A type of dementia characterized by cognitive decline, visual hallucinations, and parkinsonian motor symptoms. It is caused by abnormal protein deposits called Lewy bodies in the brain.
  • Huntington's disease: A genetic disorder causing progressive brain damage, leading to uncontrolled movements, emotional problems, and loss of thinking ability.
  • Alzheimer's disease: A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • p38 alpha kinase: An enzyme involved in cellular processes related to inflammation and stress responses. Neflamapimod specifically inhibits this enzyme.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB): A scale used to measure the severity of dementia symptoms across six domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.
  • Mini-Mental State Examination (MMSE): A widely used test of cognitive function that assesses orientation, attention, memory, language, and visual-spatial skills.
  • Neuropsychiatric Inventory (NPI): An assessment tool that measures various behavioral and psychological symptoms commonly seen in dementia patients.
  • Timed Up and Go (TUG) test: A simple test used to assess a person's mobility and risk of falling, measuring the time it takes to stand up from a chair, walk a short distance, turn around, walk back, and sit down.
  • Electroencephalogram (EEG): A test that records electrical activity in the brain using small, metal discs (electrodes) attached to the scalp.
  • Cerebrospinal fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, often analyzed for biomarkers of neurological diseases.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track disease progression or treatment effects.

References

  1. https://clinicaltrials.gov/study/NCT04001517
  2. https://clinicaltrials.gov/study/NCT05869669
  3. https://clinicaltrials.gov/study/NCT03980938
  4. https://clinicaltrials.gov/study/NCT03402659